Open an account

Coherus Oncology

CHRS · NASDAQ

$1.00+$0.0413 (+4.31%)TodayMarket closed ·
Prev close $0.9587

About CHRS

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 147 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).

Employees
145
Headquarters
Redwood City, California
Listed
Nov 6, 2014
Sector
Health Care
Industry
Biotechnology
Website
coherus.com

CHRS key statistics

Market cap
154.50M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.68M
Volume
967.71K
Open price
$0.96
High today
$1.03
Low today
$0.955
52 Week high
$2.62
52 Week low
$0.94

Coherus Oncology (CHRS) at a glance

As of Oct 20, 2026, Coherus Oncology (CHRS) shares are priced at $1.00, giving the company a market cap of 154.50M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.955 and $1.03. The current price is 4.7% above the day's low and 2.9% below its high.

Volume so far is 967.71K shares, below the average of 1.68M shares a day.

Over the past year Coherus Oncology has ranged from $0.94 to $2.62, and now sits 4% of the way up that range.

Coherus Oncology met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.13 per share against an estimate of -$0.204.

The average analyst price target is $7.14, 614.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $7.14
Low
$4.04
Now
$1.00
High
$10.50

CHRS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 28.5% on average.

  1. Q3 FY24: reported -$0.01 per share against an estimate of -$0.136
  2. Q4 FY24: reported -$0.28 per share against an estimate of -$0.134
  3. Q1 FY25: reported -$0.35 per share against an estimate of -$0.2366
  4. Q2 FY25: reported -$0.34 per share against an estimate of -$0.3026
  5. Q3 FY25: reported -$0.33 per share against an estimate of -$0.3315
  6. Q4 FY25: reported -$0.34 per share against an estimate of -$0.3502
  7. Q1 FY26: reported -$0.25 per share against an estimate of -$0.2788
  8. Q2 FY26: reported -$0.13 per share against an estimate of -$0.204

CHRS news

  • Press releasePRNewswire

    Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Coherus BioSciences's Earnings Outlook

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releasePRNewswire

    Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks

  • Press releasePRNewswire

    Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

  • Press releaseGlobe Newswire

    The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

  • Earnings Scheduled For November 6, 2025

Similar companies

Companies in the same industry as Coherus Oncology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.